Erlotinib in Previously Treated Non–Small-Cell Lung Cancer | Zendy

Frances A. Shepherd | Zendy; José Rodrigues Pereira | Zendy; TudorEliade Ciuleanu | Zendy; Eng Huat Tan | Zendy; Vera Hirsh | Zendy; Sumitra Thongprasert | Zendy; Daniel de Castro | Zendy; Savitree Maoleekoonpiroj | Zendy; Michael Smylie | Zendy; Renato Martins | Zendy; Maximiliano Van Kooten | Zendy; Mircea Dediu | Zendy; B. Findlay | Zendy; Dongsheng Tu | Zendy; D. Johnston | Zendy; Andrea Bezjak | Zendy; Gary M. Clark | Zendy; P. Santabárbara | Zendy; Lesley Seymour | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Author(s) -

Frances A. Shepherd,

José Rodrigues Pereira,

TudorEliade Ciuleanu,

Eng Huat Tan,

Vera Hirsh,

Sumitra Thongprasert,

Daniel de Castro,

Savitree Maoleekoonpiroj,

Michael Smylie,

Renato Martins,

Maximiliano Van Kooten,

Mircea Dediu,

B. Findlay,

Dongsheng Tu,

D. Johnston,

Andrea Bezjak,

Gary M. Clark,

P. Santabárbara,

Lesley Seymour

Publication year - 2005

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa050753

Subject(s) - erlotinib , medicine , lung cancer , hazard ratio , erlotinib hydrochloride , chemotherapy , randomization , placebo , performance status , oncology , surgery , epidermal growth factor receptor , gastroenterology , cancer , randomized controlled trial , confidence interval , pathology , alternative medicine

We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research